DOCSLIB.ORG

Pdl Biopharma, Inc. Pdl Biopharma, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pdl Biopharma, Inc. Pdl Biopharma, Inc PDL BIOPHARMA, INC. PDL BIOPHARMA, INC. PDL BIOPHARMA, 2007 ANNUAL REPORT 2007 ANNUAL 1400 Seaport Blvd. Redwood City, CA 94063 Tel: 650-454-1000 Fax: 650-454-2000 ANNUAL REPORT www.pdl.com MANAGEMENT Transfer Agent and Registrar Stock Listing BNY Mellon Shareowner Services Our common stock trades on the NASDAQ L. Patrick Gage, Ph.D. P. O. Box 358015 Global Select Market under the symbol Interim Chief Executive Officer Pittsburgh, PA 15252-8015 “PDLI.” We had never declared any cash Richard Murray, Ph.D. dividends on our capital stock prior to or Executive Vice President and March 2008, when we declared a $4.25 480 Washington Blvd. Chief Scientific Officer per share of common stock dividend. Jersey City, NJ 07310-1900 We also announced in March 2008 that we Andrew Guggenhime Tel: 800-522-6645 (US) plan to spin off our biotechnology related Senior Vice President and 201-680-6578 (outside US) assets, which we intend to complete by Chief Financial Officer TDD for hearing impaired: the end of 2008, and that thereafter we Mark McCamish, M.D., Ph.D. 800-231-5469 (US) plan to distribute future antibody human- Senior Vice President and 201-680-6610 (outside US) ization royalty revenues, net of any operat- Chief Medical Officer www.bnymellon.com/shareowner/isd ing expenses, debt service and income Jaisim Shah Independent Auditors taxes, to our stockholders. Senior Vice President, Marketing Ernst & Young LLP Price Range of Common Stock and Business Affairs Palo Alto, CA As of March 31, 2008, we had approxi- Francis Sarena Corporate Counsel mately 242 common stockholders of record. Because brokers and other Our antibody humanization technology has Executive Director, DLA Piper US LLP institutions hold many of these shares on Chief Legal Officer and Secretary San Francisco, CA made possible nine life–changing medicines. behalf of stockholders, we are unable to We’re currently focused on leveraging our BOARD OF DIRECTORS Annual Meeting estimate the total number of stockhold- 2008 Annual Meeting of Stockholders will ers represented by the record holders, but core expertise to discover and develop a new Karen A. Dawes be held on May 28, 2008 at 9 a.m. at PDL we believe that they are well in excess of L. Patrick Gage, Ph.D. stream of innovative antibody products tar- BioPharma, 1400 Seaport Blvd., Redwood record holders. The following table sets geting oncology and immunologic diseases, Brad S. Goodwin City, CA 94063 forth the quarterly high and low bid prices Joseph Klein III while we work to optimize the value of our for a share of PDL common stock for the Laurence Jay Korn, Ph.D. CORPORATE GOVERNANCE fiscal years ended December 31, 2006 and successful antibody humanization royalties. Richard Murray, Ph.D. DOCUMENTS 2007, as reported by the NASDAQ Global Jon S. Saxe, Esq. PDL’s corporate governance guidelines, Select Market. annual report, SEC filings, and code of CORPORATE INFORMATION conduct for directors, officers (including 2006 High Low Corporate Headquarters our principal executive officer, principal Q1 $ 33.30 $ 27.15 1400 Seaport Blvd. financial officer and principal accounting Q2 $ 32.97 $ 16.79 Redwood City, CA 94063 officer) and employees can be obtained Q3 $ 19.95 $ 16.39 Tel: 650-454-1000 free on our website at www.pdl.com. Q4 $ 23.29 $ 18.70 Fax: 650-454-2000 Additionally, stockholders may receive www.pdl.com copies upon request to: 2007 High Low Corporate and Investor Relations Q1 $ 21.69 $ 18.78 PDL BioPharma, Inc. Q2 $ 27.46 $ 23.02 1400 Seaport Blvd. Q3 $ 24.16 $ 20.23 Redwood City, CA 94063 Q4 $ 21.31 $ 17.72 Tel: 650-454-1508 Fax: 650-454-2000 Design: Helene Sherlock l Photograph: Kingmond Young LETTER TO OUR STOCKHOLDERS May 2008 The past year has been one of tremendous change for PDL BioPharma, marked by a series of events that, by the end of 2008, should result in two separate public companies: a streamlined antibody–focused bio- technology organization that we plan to spin-o from PDL BioPharma, and the current company, which will administer the successful antibody humanization royalties. We believe these two separate companies would enable investors to realize the full value of each of PDL BioPharma’s current assets. Our decisions and actions in 2007 were aimed at optimizing the value of each of our core assets. First, we recognized the need for our Board of Directors and management to undertake a thorough strategic review process. As a result, we rst concluded that our commercial products were no longer a strategic t for the company, and we began a process to sell these assets. We subsequently decided also to seek buyers for the company as a whole or for our other individual assets – a decision we felt could deliver additional value for our stockholders. By the end of 2007, we were pleased to announce an agreement to sell our oncology product, IV Busulfex, to Otsuka Pharmaceuticals. In early 2008, we then announced an agreement to sell our commercial and cardiovascular assets, consisting of product rights to Cardene, Retavase and ularitide, to EKR Therapeutics. Shortly thereafter, we entered into an agreement to sell our large–scale manufacturing facility to Genmab. We determined that each transaction re ected the value of the particular asset and provided the best return for our stockholders in light of other alternatives. In total, these three transactions pro- vided initial proceeds of over $500 million in cash, which we subsequently announced would be returned to stockholders through a special cash dividend. In March 2008, we ended the formal sale process for the company and announced a restructuring to focus on our core expertise in antibody discovery and development. As we then assessed our remaining core assets – our biotechnology operations and our royalty stream – we determined that separating them would best enable our stockholders to realize their values fully and independently. To achieve this separation, in April 2008, we announced our intent to spin o the bio- technology component of our business from our antibody humanization royalty stream. This transaction is anticipated to occur by the end of 2008. Following the spin-o of the biotechnology operations, PDL BioPharma would retain rights to the an- tibody humanization royalty revenues from all current and future licensed products. These include the products on which PDL currently generates royalties, which totaled $221 million in revenues for the full year of 2007. We look forward to additional potential royalties from one recently approved product and another in registration, and there are many more in various stages of development that could contribute to growth of this royalty stream prior to the expiration of our humanization patents in 2014. In parallel to the spin–o process, we are pursuing e orts to sell or otherwise monetize some or all of the value of the antibody humanization royalties, and we believe our plan to separate them from our biotech- nology assets enhances our ability to e ect such a transaction. Subsequent to the spin–o , PDL intends to distribute future royalty revenues, net of any operating expenses, debt service and income taxes, to stockholders. As a separate public company, our streamlined biotechnology operations would continue to focus on the discovery and development of innovative antibodies in the areas of oncology and immunology. We will apply our experience and knowledge in novel target identi cation and antibody engineering to create new therapies, extending our current pipeline of promising antibody product candidates. We are also excited about leveraging our core antibody technologies with breakthrough protein engi- neering approaches to optimize antibody therapeutics. Such capabilities form the backbone for our biotechnology operations and suggest a stream of antibody candidates for our development pipeline going forward. Of course, the more visible area of value creation for the new company in the near term will be advance- ment of our clinical candidates, led by daclizumab in multiple sclerosis (MS) and other immunologic dis- eases such as asthma. Results from PDL-designed and -executed placebo-controlled phase 2 clinical trials of daclizumab in MS and in asthma met their primary endpoints, and we are advancing this promising antibody in both areas of signi cant unmet need. We are pleased to continue to work on the MS program with Biogen Idec, the leader in this therapeutic eld. We also continue to work with them on volociximab, our antibody currently being tested in ovarian and lung cancers. Two additional innovative antibodies from our discovery research are in earlier stages of development. HuLuc63 is in phase 1 evaluation for multiple myeloma, and during 2008, we plan to extend the program with combination therapy trials and fully explore the antibody’s potential in other disease areas. PDL192 is another exciting “ rst-in-class” antibody that we plan to advance into clinical development in 2008. PDL192 has demonstrated compelling activity in preclinical solid tumor models, the data for which were rst presented to the scienti c community in the spring of 2008, and we look forward to moving this important program ahead in the coming years. Now that we’ve set our strategic course, our focus turns to the implementation of a timely and smooth spin-o transaction. A key objective is to determine the leadership, including new CEOs for PDL and for the biotechnology company post-separation. As our planning continues during the year, we intend to update you with additional details regarding the structure, leadership, and nancial operations of both companies. We would like to close with our sincere thanks to our stockholders, employees, and partners without whose support we would not be able to move forward successfully on our stated path.
Load more

Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,663,587 B2 Hsieh Et Al
    USOO9663587B2 (12) United States Patent (10) Patent No.: US 9,663,587 B2 Hsieh et al. (45) Date of Patent: May 30, 2017 (54) IL-17 BINDING PROTEINS 4,753,894 A 6, 1988 Frankel et al. 4,816,397 A 3, 1989 BOSS et al. 4,816,567 A 3/1989 Cabilly et al. (71) Applicant: AbbVie Inc., North Chicago, IL (US) 4,880,078 A 11/1989 Inoune et al. 4,943,533 A 7, 1990 Mendelsohn et al. (72) Inventors: Chung-Ming Hsieh, Newton, MA 4.946,778 A 8, 1990 Ladner et al. (US); Margaret Hugunin, North 4,980,286 A 12/1990 Morgan et al. Grafton, MA (US); Anwar Murtaza, 5,006,309 A 4, 1991 Khali1 et al. 5,063,081 A 11/1991 Cozzette et al. Westborough, MA (US); Bradford L. 5,089,424 A 2f1992 Khali1 et al. McRae, Northborough, MA (US); 5,128,326 A 7, 1992 Balazs et al. Yuliya Kutskova, Northborough, MA 5,135,875 A 8, 1992 Meucci et al. (US); John E. Memmott, Framingham, 5,223,409 A 6/1993 Ladner et al. MA (US); Jennifer M. Perez, 5,225,539 A 7, 1993 Winter 5,241,070 A 8, 1993 Law et al. Worcester, MA (US); Suju Zhong, 5,242,828 A 9/1993 Bergstrom et al. Shrewsbury, MA (US); Edit Tarcsa, 5,258.498 A 11/1993 Huston et al. Westborough, MA (US); Anca 5,290,540 A 3, 1994 Prince et al. Clabbers, Rutland, MA (US); Craig 5,294.404 A 3/1994 Grandone et al.
    [Show full text]
  • BMS's Alternatives to Imclone
    October 07, 2008 BMS's alternatives to ImClone Evaluate Vantage Bristol-Myers Squibb’s failure to acquire ImClone, a deal which the pharma giant claimed to be “a strategically and financially sound add-on”, throws open the question as to whether BMS remains committed to an oncology-based biotech acquisition to bolster its pipeline. Assuming BMS keeps faith with this strategy, yesterday’s official statement referred to “other alternatives open to the company” as part of the reason to abort the ImClone deal, an analysis of peer group data from EvaluatePharma reveals a handful of companies that may provide a suitable alternative for BMS, including Alexion Pharmaceuticals, PDL BioPharma and Medarex. Flush with cash Including the $1bn BMS will receive when Eli Lilly completes its acquisition of ImClone, the group is expected to hold around $9.4bn in cash by the end of the year. In this context, all the following companies are comfortably within BMS’s purchasing power, especially in light of the recent declines for most biotech stocks. This analysis includes companies with an attractive monoclonal antibody platform technology, antibody candidates in mid-to-late stage clinical trials to treat various cancers, and ones that also still have a market capitalisation greater than $500m. YTD 2014 Market Enterprise share Pharma Current sales / Cap. Value Lead antibody Partner? price class status royalty ($m) ($m) change ($m) Anti- Alexion 3,010 3,109 3.13% ALXN6000 CD200 Phase II - no Pharmaceuticals MAb Anti- United 2,164 2,199 (2.88%) 3F8 MAb GD2
    [Show full text]
  • Pdl Biopharma 2005 Annual Report 1
    In 2005, we achieved our commercial transformation. Looking ahead, our vision is 2010. 2005 Annual Report 2 LETTER TO SHAREHOLDERS 6 OUR PRODUCTS 14 OUR PIPELINE 20 OUR PERFORMANCE 24 OUR MANAGEMENT 25 FINANCIAL REPORT 102 CORPORATE INFORMATION 104 CODE OF CONDUCT A clear vision: from Through strategic acquisitions and partnerships, we have become a commercial biopharmaceutical company, reflected in our new name, PDL BioPharma. We have a portfolio of acute-care hospital products being commercialized by our own U.S. marketing and sales force. We have a growing and diverse revenue base, six promising product candidates in clinical development and a strategy to fuel our pipeline through internal discovery and collaboration. PDL BIOPHARMA 2005 ANNUAL REPORT 1 ◆ We hit our goal in 2005 to create a commercial business, while enhancing shareholder value. We’ve transformed our business and now we’re focused on becoming a sustainable and growing biopharmaceutical company. 2005 to Vision 2010 We have set our sights even higher over the next five years and as part of our Vision 2010 aims, we are executing the strategies that will enable us to solidify our position as a top-tier biopharmaceutical company. STRATEGY 1 ◆ Reach or maintain No. 1 or No. 2 dollar market shares for marketed drugs STRATEGY 2 ◆ Develop and launch at least three products STRATEGY 3 ◆ Establish a deeper, stronger pipeline STRATEGY 4 ◆ Expand commercial operations to Europe STRATEGY 5 ◆ Sustainably grow revenue and earnings performance 2 LETTER TO SHAREHOLDERS To Our Shareholders… MARK McDADE CHIEF EXECUTIVE OFFICER 2005 was a year of dramatic change.
    [Show full text]
  • PDL BIOPHARMA, INC. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2006 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-19756 PDL BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 94-3023969 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 34801 Campus Drive Fremont, CA 94555 (Address of principal executive offices) Telephone Number (510) 574-1400 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and, (2) has been subject to such filing requirements for the past 90 days: Yes x No ¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer x Accelerated filer ¨ Non-accelerated filer ¨ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x As of May 3, 2006 there were 114,467,120 shares of the Registrant’s Common Stock outstanding.
    [Show full text]
  • PDL BIOPHARMA, INC. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2006 OR ¨ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission File Number: 0-19756 PDL BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 94-3023969 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 34801 Campus Drive Fremont, CA 94555 (Address of principal executive offices and Zip Code) (510) 574-1400 (Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and, (2) has been subject to such filing requirements for the past 90 days: Yes x No ¨ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer x Accelerated filer ¨ Non-accelerated filer ¨ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x As of November 3, 2006, there were 115,226,181 shares of the Registrant’s Common Stock outstanding.
    [Show full text]
  • Assessment of the Evolution of Cancer Treatment Therapies
    Cancers 2011, 3, 3279-3330; doi:10.3390/cancers3033279 OPEN ACCESS cancers ISSN 2072-6694 www.mdpi.com/journal/cancers Review Assessment of the Evolution of Cancer Treatment Therapies Manuel Arruebo 1,2, Nuria Vilaboa 2,3, Berta Sáez-Gutierrez 1,4,5, Julio Lambea 1,4,5, Alejandro Tres 1,4,5, Mónica Valladares 6 and África González-Fernández 7,* 1 Instituto de Nanociencia de Aragón (INA), Mariano Esquillor, Edif. I+D, University of Zaragoza, Zaragoza 50018, Spain; E-Mails: [email protected] (M.A.); [email protected] (B.S.); [email protected] (J.L.); [email protected] (A.T.) 2 CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza 50018, Spain; E-Mail: [email protected] (N.V.) 3 Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, Madrid 28046, Spain 4 Servicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Avda. San Juan Bosco 50009, Zaragoza, Spain 5 Instituto Aragonés de Ciencias de la Salud (I+CS), Avda. Gómez Laguna, 25, Zaragoza 50009, Spain 6 Lonza Biologics Porriño, A relva s/n, Porriño (Pontevedra) 36410, Spain; E-Mail: [email protected] (M.V.) 7 Immunology Department, Biomedical Research Center (CINBIO), University of Vigo, Campus Lagoas Marcosende, Vigo (Pontevedra) 36310, Spain * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +34-986812625; Fax: +34-986-812556. Received: 16 June 2011; in revised form: 7 July 2011 / Accepted: 8 August 2011 / Published: 12 August 2011 Abstract: Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases.
    [Show full text]
  • | Hai Lama Mtu Matutut Kita Mama
    |HAI LAMA MTU MATUTUTUS009962408B2 KITA MAMA (12 ) United States Patent ( 10 ) Patent No. : US 9 , 962, 408 B2 Deisher ( 45 ) Date of Patent: May 8 , 2018 ( 54 ) COMPOSITIONS AND METHODS TO (52 ) U . S . CI. INHIBIT STEM CELL AND PROGENITOR CPC . .. A61K 35 /28 (2013 . 01 ) ; A61K 31/ 573 CELL BINDING TO LYMPHOID TISSUE AND ( 2013 .01 ) ; A61K 39 /3955 ( 2013 .01 ) ; CO7K FOR REGENERATING GERMINAL 16 /28 78 ( 2013 .01 ) ; AIK 35 / 12 (2013 .01 ) ; CENTERS IN LYMPHATIC TISSUES A61K 2039 /505 ( 2013 .01 ) ; C12N 5 /0602 ( 2013 .01 ) ( 71 ) Applicant : Ave Maria Biotechnology LLC , (58 ) Field of Classification Search Seattle , WA (US ) CPC .. .. A61K 31/ 573 ; A61K 35 /12 , A61K 35 / 28 ; C12N 5 /0602 ( 72 ) Inventor : Theresa Deisher, Seattle , WA (US ) USPC .. .. .. .. .. 435 /375 ; 424 /93 . 7 ; 514 / 1 ( 73 ) Assignee : AVM Biotechnology LLC , Seattle , WA See application file for complete search history . (US ) (56 ) References Cited ( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U . S . C . 154 (b ) by 0 days . days . PUBLICATIONS Kolf et al ., 2007 , Arthritis Research & Therapy, vol. 9 , p . 204, 10 ( 21 ) Appl. No .: 15 /410 , 759 pages .* Alenzi et al. , 2011 , African Journal of Biotechnology , vol. 10 ( 86 ), (22 ) Filed : Jan . 19 , 2017 pp . 19929 - 19940 . * Wu et al. , 2012 , Aging Research reviews, vol. 11 , p . 32 - 40 . * (65 ) Prior Publication Data Steinert et al. , 2007 , Arthritis Research & therapy, vol . 9 , No . 3 , 213 , p . 1 - 15 . * US 2017 /0128493 A1 May 11, 2017 Li et al. , 2009 , Transplant Immunology , vol. 21, p .
    [Show full text]
  • Assessment of the Evolution of Cancer Treatment Therapies
    Cancers 2011, 3, 3279-3330; doi:10.3390/cancers3033279 OPEN ACCESS cancers ISSN 2072-6694 www.mdpi.com/journal/cancers Review Assessment of the Evolution of Cancer Treatment Therapies Manuel Arruebo 1,2 , Nuria Vilaboa 2,3 , Berta Sáez-Gutierrez 1,4,5 , Julio Lambea 1,4,5 , Alejandro Tres 1,4,5 , Mónica Valladares 6 and África González-Fernández 7,* 1 Instituto de Nanociencia de Aragón (INA), Mariano Esquillor, Edif. I+D, University of Zaragoza, Zaragoza 50018, Spain; E-Mails: [email protected] (M.A.); [email protected] (B.S.); [email protected] (J.L.); [email protected] (A.T.) 2 CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza 50018, Spain; E-Mail: [email protected] (N.V.) 3 Hospital Universitario La Paz-IdiPAZ, Paseo de la Castellana 261, Madrid 28046, Spain 4 Servicio de Oncología Médica, Hospital Clínico Universitario Lozano Blesa, Avda. San Juan Bosco 50009, Zaragoza, Spain 5 Instituto Aragonés de Ciencias de la Salud (I+CS), Avda. Gómez Laguna, 25, Zaragoza 50009, Spain 6 Lonza Biologics Porriño, A relva s/n, Porriño (Pontevedra) 36410, Spain; E-Mail: [email protected] (M.V.) 7 Immunology Deapartment, Biomedical Research Center (CINBIO), University of Vigo, Campus Lagoas Marcosende, Vigo (Pontevedra) 36310, Spain * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +34-986812625; Fax: +34-986-812556. Received: 16 June 2011; in revised form: 7 July 2011 / Accepted: 8 August 2011 / Published: 12 August 2011 Abstract: Cancer therapy has been characterized throughout history by ups and downs, not only due to the ineffectiveness of treatments and side effects, but also by hope and the reality of complete remission and cure in many cases.
    [Show full text]